This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
The Zacks Analyst Blog Highlights CareCloud, DaVita, RadNet, SkyWest and American Express
by Zacks Equity Research
CareCloud, DaVita, RadNet, SkyWest and American Express are included in this Analyst Blog.
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
by Zacks Equity Research
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
5 Stocks to Gain as Service Side of the Economy Bounces Back
by Tirthankar Chakraborty
With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).
Here's Why You Should Hold McKesson (MCK) in Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Veeva Systems' (VEEV) Vault EDC to Boost Tigermed's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to streamline key processes to accelerate study builds and make mid-study amendments with no downtime.
DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex
by Zacks Equity Research
DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $143.18, representing a -0.46% change from its previous close.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
by Zacks Equity Research
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Philips (PHG) Boosts Precision Diagnosis With AI Platform
by Zacks Equity Research
Philips (PHG) boosts its Precision Diagnosis portfolio with an AI-powered ultrasound platform, strengthening its Diagnosis & Treatment segment.
Play Likely Earnings Beat With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks MGM Resorts International (MGM), Burlington Stores (BURL), Sterling Infrastructure Inc (STRL), Dropbox (DBX) and DaVita (DVA) are likely to beat on the bottom line in their upcoming releases.
Waters (WAT) Expands Mass Spectrometer Portfolio With Xevo MRT
by Zacks Equity Research
Waters (WAT) boosts MS offerings with the launch of Xevo MRT, strengthening its Waters operating segment's portfolio.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Patterson Companies' (PDCO) New Launch to Boost Patient Service
by Zacks Equity Research
Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.
DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in kidney care.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Philips (PHG) Boosts Medical Imaging Footprint With New Move
by Zacks Equity Research
Philips (PHG) expands its international footprint with the wide availability of VeriSight Pro 3D to several Hong Kong hospitals, strengthening its Diagnosis & Treatment segment.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. Gross margins improve. However, the rising cost of products is a concern.